Advances in combination therapy for the treatment of estrogen receptor positive breast cancer
Authors:
- Lijuan LiuLLLijuan Liu
- Zhihao ZhaoZZZhihao Zhao
- Feiwan ZouFZFeiwan Zou
- Wukun LiuWLWukun Liu
- Yunlong LuYLYunlong Lu
- 12 June 2025
- journal article
- Published by Elsevier in Chinese Chemical Letters
- Vol. 36 (10)
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (XPT82204181)
- Jiangsu Commission of Health (Z2021057)
- State Key Laboratory of Coordination Chemistry
- Jiangsu Provincial Key Research and Development Program (BE2023840)
- Priority Academic Program Development of Jiangsu Higher Education Institutions (zyyzdxk-2023083)
This publication has 112 references indexed in Scilit:
- Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2Annals of Oncology, 2023
- Elacestrant: First ApprovalDrugs, 2023
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast CancerDrugs, 2020
- Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancerAnnals of Oncology, 2020
- Emerging roles of aerobic glycolysis in breast cancerClinical and Translational Oncology, 2019
- Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trialInternational Journal of Cancer, 2018
- Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast CancerJAMA Oncology, 2018
- Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cellsBreast Cancer Research and Treatment, 2008
- Histone deacetylase inhibition and estrogen signalling in human breast cancer cellsBiochemical Pharmacology, 2004